Answers are grounded in this paper and cite their sources.
Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) is emerging as a novel risk factor for many nonhematological diseases. Although some studies suggest that CHIP is associated with adverse kidney outcomes, the results are conflicting across cohorts. Methods: In this secondary analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, we assessed the association between CHIP and kidney function in 9434 community-dwelling adults aged > 70 years. At baseline, participants were free of cardiovascular disease (CVD) and major life-limiting illness. In addition, we performed meta-analysis of published cohorts investigating the association between CHIP and incident kidney function decline. Results: CHIP, with considerable heterogeneity. Conclusion: We propose that the effect of CHIP is modified by participant factors, including comorbidities, partly accounting for heterogeneity across cohorts. This work contributes to a growing understanding of the interplay between CHIP and disease, and considerations in translating findings from large observational studies to individuals with CHIP.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: